Should we sound the alarm? Dysplasia and colitis-associated colorectal Cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 8, 2011, Pages 1881-1886

  Ren, Lin Lin ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal cancer; Dysplasia; Surveillance; Ulcerative colitis

Indexed keywords

EID: 84858138634     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (53)

1. Ahmadi A, Polyak S, Draganov PV (2009). Colorectal cancer surveillance in inflammatory bowel disease: The search continues. World J Gastroenterol, 15, 61-6.
2. Askling J, Dickman PW, Karlen P, et al (2001). Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology, 120,1356-62.
3. Brackmann S, Andersen SN, Aamodt G, et al (2009). Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis, 15, 9-16.
4. Bernstein CN, Blanchard JF, Metge C, et al (2003). Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol, 98, 2784-8.
5. Bernstein CN, Shanahan F, Weinstein WM (1994). Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet, 343,71-4.
6. Crohn BB RH (1925). The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci, 170, 220-8.
7. Chow DK, Leong RW, Tsoi KK, et al (2009). Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol, 104, 647-54.
8. Connell WR, Talbot IC, Harpaz N, et al (1994). Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut, 35, 1419-23.
9. Eaden J (2004). Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther, 20 Suppl 4, 24-30.
10. Eaden JA, Mayberry JF (2002). Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut, 51 Suppl 5, V10-2.
11. Eaden JA, Abrams KR, Mayberry JF (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-35.
12. Eaden J, Abrams K, Ekbom A, et al (2000). Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther, 14, 145-53.
13. Ekbom A, Helmick C, Zack M, et al (1990). Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med, 323, 1228-33.
14. Gupta RB, Harpaz N, Itzkowitz S, et al (2007). Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology, 133, 1099-105.
15. Gorfine SR, Bauer JJ, Harris MT, et al (2000). Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum, 43, 1575-81.
16. Hurlstone DP. (2008) The detection of flat and depressed colorectal lesions: which endoscopic imaging approach? Gastroenterology, 135, 338-43.
17. Iacucci M, de Silva S, Ghosh S (2010). Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol, 24, 127-33.
18. Itzkowitz SH, Harpaz N (2004). Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology, 126, 1634-48.
19. Jess T, Loftus EV Jr, Velayos FS, et al (2007). Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted county, Minnesota. Am J Gastroenterol, 102, 829-36.
20. Jess T, Loftus EV, Jr., Velayos FS, et al (2006). Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis, 12, 669-76.
21. Jess T, Loftus EV, Jr., Velayos FS, et al (2006). Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology, 130, 1039-46.
22. Kulaylat MN, Dayton MT (2010). Ulcerative colitis and cancer. J Surg Oncol, 101, 706-12.
23. Kim BJ, Yang SK, Kim JS, et al (2009). Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. J Gastroenterol Hepatol, 24, 667-71.
24. Kornfeld D, Ekbom A, Ihre T (1997). Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut, 41, 522-5.
25. Lichtenstein GR, Rutgeerts P (2010). Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis, 16,338-46.
26. Leong RW, Koo JH (2009). Colorectal cancer in inflammatory bowel disease. J Gastroenterol Hepatol, 24, 503-5.
27. Lakatos PL, Lakatos L (2008). Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol, 14, 3937-47.
28. Lutgens MW, Vleggaar FP, Schipper ME, et al (2008). High frequency of early colorectal cancer in inflammatory bowel disease. Gut, 57, 1246-51.
29. Lakatos L, Mester G, Erdelyi Z, et al (2006). Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis, 12, 205-11.
30. Loftus EV, Jr., Harewood GC, Loftus CG, et al (2005). PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut, 54, 91-6.
31. Lim CH, Dixon MF, Vail A, et al (2003). Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut, 52, 1127-32.
32. Matula S, Croog V, Itzkowitz S, et al (2005). Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol, 3, 1015-21.
33. Ooi CJ, Fock KM, Makharia GK, et al (2010). The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol, 25, 453-68.
34. Pardi DS, Loftus EV Jr, Kremers WK, et al (2003). Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology, 124, 889-93.
35. Rubin DT, LoSavio A, Yadron N, et al (2006). Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol, 4, 1346-50.
36. Rutter M, Saunders B, Wilkinson KH, et al (2006). Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology, 130, 1030-8.
37. Rutter M, Saunders B, Wilkinson K, et al (2004). Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 126, 451-9.
38. Rutter M, Saunders B, Schofield G, et al (2004). Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut, 53, 256-60.
39. Riddell RH, Goldman H, Ransohoff DF, et al (1983). Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol, 14, 931-68.
40. Stein SL, Michelassi F (2008). How can fecundity be preserved in patients undergoing pelvic surgery? Nat Clin Pract Gastroenterol Hepatol, 5, 308-9.
41. Scheppach W (1996). Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci, 41, 2254-9.
42. Scheppach W, Sommer H, Kirchner T, et al (1992). Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology, 103, 51-6.
43. Terdiman JP, Steinbuch M, Blumentals WA, et al (2007). 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis, 13, 367-71.
44. Tung BY, Emond MJ, Haggitt RC, et al (2001). Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med, 134, 89-95.
45. Taylor BA, Pemberton JH, Carpenter HA, et al (1992). Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum, 35, 950-6.
46. Ullman T, Croog V, Harpaz N, et al (2003). Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology, 125, 1311-9.
47. Ullman TA, Loftus EV Jr, Kakar S, et al (2002). The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol, 97, 922-7.
48. van den Broek FJ, Fockens P, van Eeden S, et al (2008). Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut, 57, 1083-9.
49. Velayos FS, Terdiman JP, Walsh JM (2005). Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol, 100, 1345-53.
50. Vera A, Gunson BK, Ussatoff V, et al (2003). Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation, 75, 1983-8.
51. Winther KV, Jess T, Langholz E, et al (2004). Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol, 2, 1088-95.
52. Yang SK, Hong WS, Min YI, et al (2000). Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol, 15, 1037-42.
53. Zisman TL, Rubin DT (2008). Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol, 14, 2662-9.